Explore

Trendline Trendline
STORM Therapeutics Secures $56M for Cancer Drug Development

STORM Therapeutics Secures $56M for Cancer Drug Development

STORM Therapeutics Secures $56M for Cancer Drug Development
Trendline Trendline
STORM Therapeutics Secures $56M for RNA-Targeting Cancer Drug Trials

STORM Therapeutics Secures $56M for RNA-Targeting Cancer Drug Trials

STORM Therapeutics Secures $56M for RNA-Targeting Cancer Drug Trials
Trendline Trendline
Greywolf Therapeutics Appoints Edwin Moses as Chair to Drive Growth in Cancer and Autoimmune Treatments

Greywolf Therapeutics Appoints Edwin Moses as Chair to Drive Growth in Cancer and Autoimmune Treatments

Greywolf Therapeutics Appoints Edwin Moses as Chair to Drive Growth in Cancer and Autoimmune Treatments
Trendline Trendline
Greywolf Therapeutics Appoints Edwin Moses as Chair Amid Promising Oncology Developments

Greywolf Therapeutics Appoints Edwin Moses as Chair Amid Promising Oncology Developments

Greywolf Therapeutics Appoints Edwin Moses as Chair Amid Promising Oncology Developments
Trendline Trendline
FDA Grants Fast Track Designation to Opna Bio's OPN-6602 for Multiple Myeloma Treatment

FDA Grants Fast Track Designation to Opna Bio's OPN-6602 for Multiple Myeloma Treatment

FDA Grants Fast Track Designation to Opna Bio's OPN-6602 for Multiple Myeloma Treatment
Trendline Trendline
Bruntwood SciTech and Cellular Origins Sign Landmark Deal for Cell Therapy Manufacturing Expansion

Bruntwood SciTech and Cellular Origins Sign Landmark Deal for Cell Therapy Manufacturing Expansion

Bruntwood SciTech and Cellular Origins Sign Landmark Deal for Cell Therapy Manufacturing Expansion
Trendline Trendline
Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development

Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development

Kivu Bioscience Appoints Mohit Trikha as CEO to Lead ADC Development
Trendline Trendline
Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth

Parabilis Medicines Strengthens Leadership with Key Appointments to Drive Growth
Trendline Trendline
Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation

Parabilis Medicines Appoints New Executives to Drive Growth and Innovation
Trendline Trendline
Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies

Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies

Adcendo ApS Secures $75 Million Series C Financing to Advance ADC Cancer Therapies
Trendline Trendline
Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence

Zealand Pharma Appoints Eric Rojas as Vice President and Head of Investor Relations, Enhancing U.S. Presence
Trendline Trendline
Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment